None listed
Conditions
Interventions
Intervention1: NEUROCAF: Oral administration of single dose of NEUROCAF at the morning for 84 days
Control Intervention1: Placebo: Oral administration of single dose of placebo at the morning for 84 d
Sponsors
Vidya Herbs Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Should not be an any medication for cognition and other neurological disorders 2. Post-menopausal women 3. Must be willing and able to give informed consent and comply with the study procedures.
Exclusion criteria
Exclusion criteria: 1. Subjects with history of Neurogenerative disorder, including Parkinsonâ??s disorder,Psychiatric disorders ,Uncontrolled / serious medical illness including diabetes, liver disease, hypertension,Cardiac Disease/Neurological Problems,Auto-immune disease (rheumatoid arthritis, lupus, type 1 diabetes),Gastrointestinal tract bleeding / peptic ulcer disease 2. Subjects having symptoms of viral infection, including COVID-19 infection 3. Subjects who may be allergic to any of the natural constituents of the Investigational Product. 4. Known HIV or Hepatitis B positive or any other immuno-compromised state 5. Subjects on any other medical or clinical investigation or on any nutrition supplements and dietary regime. 6. Subjects visually or mentally handicapped or having difficulty to communicate 7. History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. 8. Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study. 9. Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Bio markers of Parkinsons DiseaseTimepoint: Day 0, Day 84 | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in geriatric parameters Timepoint: Day 0, Day 42, Day 84;Safety of NEUROCAFTimepoint: Day 0, Day 42, Day 84 | — |
Countries
India
Contacts
Public ContactJestin V Thomas
Leads Clinical Research and Bio Services Pvt. Ltd
Outcome results
None listed